Amoxiclav powder for injection 600mg №5 fl.


More info

Amoxiclav powder for injection 600mg №5 fl.

pharmachologic effect

Amoxiclav is a broad-spectrum antibiotic; contains semi-synthetic penicillin amoxicillin and b-lactamase inhibitor clavulanic acid. Clavulanic acid inhibits most clinically significant b-lactamases (types 2, 3, 4, and 5 according to the Richmond Sykes classification) produced by Staphylococcus spp., Escherichia coli, Proteus mirabilis, Haemophilus influenzae, Moraxella catarrhalis, Bacteroides spp. Inactive against b-lactamase type 1, produced by Enterobacter spp., Morganella morganii, Pseudomonas aeruginosa, Serratia spp., Acinetobacter spp.
This combination provides a high bactericidal activity of Amoxiclav (including in relation to amoxicillin-resistant microorganism strains). Clavulanic acid, having a higher affinity for b-lactamase than amoxicillin, forms a stable deactivated complex with the enzyme, preventing the enzymatic degradation of amoxicillin under the action of b-lactamase.
Thus, Amoxiclav acts bactericidal on a wide range of gram-positive and gram-negative bacteria (including strains that have become resistant to beta-lactam antibiotics due to the production of b-lactamase).
Amoxiclav is active against aerobic gram-positive bacteria: Streptococcus spp. (including Streptococcus pneumoniae, Streptococcus viridans, Streptococcus milleri, ryptows rye, Streptococcus pyogenes, Streptococcus bovis), Enterococcus faecium, Staphylococcus aureus (except for methicillin-resistant strains), Staphylococcus epitheypoury, aureus, Staphylococcus aureus (except methicillin-resistant strains), Staphylococcus epitheypoury, aureus, Staphylococcus aureus (except methicillin-resistant strains), Staphylococcus epitheypush, p'eurectus, aureus (except methicillin-resistant strains), Staphylococcus epiderheypush, apycarty, aureus, Staphylococcus aureus (except methicillin-resistant strains) monocytogenes, Nocardia asteroides; aerobic gram-negative bacteria: Aeromonas spp., Bordetella pertussis, Brucella spp., Campylobacter jejuni, Campylobacter coli, Citrobacter spp. (moderately sensitive), Escherichia coli, Gardnerella vaginalis, Haemophilus ducreyi, Haemophilus influenzae, Helicobacter pylori, Klebsiella spp., Legionella pneumophila, Moraxella catarrhalis, Morganella spp. (moderately sensitive), Neisseria gonorrhoeae, Neisseria meningitidis, Pasteurella multocida, Proteus mirabilis, Proteus vulgaris, Providencia spp., Salmonella spp., Shigella spp., Vibrio cholerae, Yersinia enterocolitica (Shigella spp., Vibrio cholerae, Yersinia enterocolitica (Shigella spp., Vibrio cholerae, Yersinia enterocolitica (Shigella spp., Vibrio cholerae, Yersinia enterocolitica (Shigella spp., Vibrio cholerae, Yersinia enterocolitica (Shigella spp., Vibrio cholerae, Yersinia enterocolitica (Shigella spp., Vibrio cholerae, Yersinia enterocolitica (Shigella spp., Vibrio cholerae, Yersinia enterocolitica) anaerobic bacteria: Actinomyces israelii, Bacteroides spp. (including Bacteroides fragilis), Prevotella melaninogenica, Clostridium spp. (except Clostridium difficile), Peptostreptococcus spp., Eikenella corrodens, Fusobacterium spp., Propionibacterium spp., Treponema pallidum.
The drug is moderately sensitive Mycobacterium tuberculosis, Mycobacterium fortuitum, Mycobacterium bovis, Mycobacterium kansasii.
The drug is resistant to Mycobacterium chelonae.


Treatment of infectious and inflammatory diseases caused by microorganisms sensitive to the drug:
- infections of the upper respiratory tract and upper respiratory tract (including acute and chronic sinusitis, acute and chronic otitis media, pharyngeal abscess, tonsillitis, pharyngitis);
- infections of the lower respiratory tract (including acute bronchitis with bacterial superinfection, chronic bronchitis, pneumonia);
- urinary tract infections;
- gynecological infections;
- infections of the skin and soft tissues;
- infections of bones and joints;
- infections of the biliary tract (cholecystitis, cholangitis);
- odontogenic infections.


- cholestatic jaundice or abnormal liver function caused by taking amoxicillin / clavulanic acid in history;
- hypersensitivity to amoxicillin, clavulanic acid or penicillins.
Precautions should be prescribed the drug for allergic reactions to cephalosporins and pseudomembranous colitis in history, liver failure, severe renal impairment.
Due to the fact that a large number of patients with infectious mononucleosis and lymphocytic leukemia who received ampicillin, the appearance of an erythematous rash was observed, the use of ampicillin antibiotics in these patients is not recommended.

Use during pregnancy and lactation

Amoxicillin and clavulanic acid pass in small quantities into breast milk.
Amoxiclav can be used during pregnancy in cases where the expected benefit to the mother outweighs the potential risk to the fetus.

Side effects
On the part of the digestive system: possible loss of appetite, nausea, vomiting, diarrhea; rarely, a transient increase in liver enzymes (ALT, AST), abnormal liver function; in rare cases - cholestatic jaundice, hepatitis, pseudomembranous colitis.
Allergic reactions: erythematous rash, pruritus, urticaria; rarely, exudative erythema multiforme, angioedema, and anaphylactic shock; in rare cases - exfoliative dermatitis, Stevens-Johnson syndrome.
Other: rarely - the development of superinfection, candidiasis.

special instructions

In the course of treatment should be monitored the function of blood, liver and kidneys.
Patients with severe impaired renal function require an adequate correction of the dosing regimen or an increase in the intervals between dosing.
In order to reduce the risk of adverse reactions from the gastrointestinal tract should take the drug during meals.
When using Amoxiclav, a false positive reaction is possible when determining the level of glucose in the urine using Benedict's reagent or Felling's solution (it is recommended to use enzymatic reactions with glucose oxidase).

Drug interaction

With simultaneous use of Amoxiclav and indirect anticoagulants, an increase in prothrombin time has been observed. Therefore, this combination is appointed with caution.
With the simultaneous use of Amoxiclav with allopurinol increases the risk of side effects such as rash.
With simultaneous use Amoxiclav enhances the toxicity of methotrexate.
The combination of Amoxicillin with rifampicin is antagonistic (there is a mutual weakening of the antibacterial action).
Amoxiclav should not be used simultaneously with bacteriostatic antibiotics (macrolides, tetracyclines), sulfonamides because of the possible reduction in the effectiveness of Amoxiclav.
With simultaneous use of Amoxiclav reduces the effectiveness of oral contraceptives.


There are no reports of death or life-threatening side effects due to overdose of the drug.
Symptoms: abdominal pain, diarrhea, vomiting; it is also possible anxiety, insomnia, dizziness; in some cases - seizures.
Treatment: in the case of a recent administration of the drug (less than 4 hours), it is necessary to wash the stomach and prescribe activated carbon to reduce the absorption of the drug; if necessary, conduct symptomatic therapy. Effective hemodialysis.

It is a pharmaceutical drug. Use only as directed by your doctor.


1 bottle of lyophilized powder contains amoxicillin (as sodium salt) 500 mg and clavulanic acid (as potassium salt) 100 mg.

Mode of application

The drug is introduced into / in (struino slowly or drip)
Adults and children over 12 years old (weighing more than 40 kg) - 1.2 g every 8 hours, with severe infections - every 6 hours.
Children 3 months - 12 years old - 30 mg / kg every 8 hours, with severe infections - every 6 hours.
Children up to 3 months. - 30 mg / kg every 8 hours,
premature and newborn - 30 mg / kg every 12 hours
Every 30 mg of Amoxiclav contains 25 mg of amoxicillin and 5 mg of clavulanic acid.
The course of treatment is 5-14 days. When reducing the severity of symptoms to continue therapy, it is recommended to switch to oral forms of the drug.
For the prevention of postoperative infections in / before anesthesia, the drug is administered at a dose of 1.2 g.
In patients with renal insufficiency, the dosage regimen should be adjusted. Amoxiclav should be administered as an intravenous injection within 20 minutes after resuspension. Do not freeze the solution.

Storage conditions
The drug should be stored in a dry place inaccessible to children at a temperature not higher than 25 ° C.
Shelf life
2 years.